**AbbVie to Invest $195 Million in North Chicago Manufacturing Expansion**
AbbVie has announced plans to invest $195 million into expanding its manufacturing plant in North Chicago, Illinois. This initiative aims to increase domestic production of active pharmaceutical ingredients (API) as part of the company’s broader commitment to invest more than $10 billion in capital within the United States.
Construction on the new API facility is scheduled to begin this fall. The expansion will boost AbbVie’s chemical synthesis capabilities, reinforcing the company’s focus on advancing treatments in neuroscience, immunology, and oncology. This development further enhances AbbVie’s U.S. manufacturing network, which already supports over 6,000 jobs across 11 facilities nationwide.
“Over the next decade, AbbVie will expand production of API, drug product, peptides, and medical devices in the U.S. to support future medical breakthroughs,” said Robert A. Michael, Chairman and CEO of AbbVie. “This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients’ lives.”
The North Chicago expansion reflects AbbVie’s strategic efforts to strengthen domestic pharmaceutical manufacturing and ensure long-term support for the development of new therapies.
